Thenappan Chandrasekar

Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (11)

Objective To compare the peri‐operative outcomes of radical prostatectomy (RP) for locally advanced, node‐positive, and metastatic prostate cancer (PCa), as determined through pathological staging, using the American College of Surgeons National Surgical Quality Improvement Project. Methods We identified RP procedures performed between 2019 and 2021. Patients were stratified by pathological staging to compare the effect of locally advanced disease (T3‐4), node positivity (N+) and metastasis (M+) vs localised PCa (T1‐2 N0 M0). Baseline demographics and 30‐day outcomes, including operating time, length of hospital stay (LOS), 30‐day mortality, readmissions, reoperations, major complications, minor complications and surgery‐specific complications, were compared between groups. Results Pathological staging data were available for 9276 RPs. Baseline demographics were comparable. There was a slightly higher rate of minor complications in the locally advanced cohort, but no significant difference in major complications, 30‐day mortality, readmissions, or rectal injuries. Node positivity was associated with longer operating time, LOS, and some slightly increased rates of 30‐day complications. RP in patients with metastatic disease appeared to be similarly safe to RP in patients with M0 disease, although it was associated with a longer LOS and slightly increased rates of certain complications. Conclusions For patients with pathologically determined locally advanced, node‐positive, and metastatic PCa, RP appears to be safe, and is not associated with significantly higher rates of 30‐day mortality or major complications compared to RP for localised PCa. This study adds to the growing body of literature investigating the role of RP for advanced PCa; further studies are needed to better characterise the risks and benefits of surgery in such patients.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Ardalanejaz Ahmad

Assistant Professor

University of Manitoba

CANADA
View details

Alicia Morgans

Dana-Farber Cancer Institute

UNITED STATES
View details

Hanan Goldberg

Assistant Professor

SUNY Upstate Medical University

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.